Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.52), versus ($0.43) reported last year. Revenue for the quarter came in at $5.53 million, versus $0 reported last year.

Financial Guidance

Based on timing expectations and projected costs for current clinical development plans, Cara expects that its existing cash and cash equivalents and available-for-sale marketable securities as of December 31, 2018 will be sufficient to fund its currently anticipated operating expenses and capital expenditures into 2021, without giving effect to any potential milestone payments under existing collaborations.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.